Skip to main content
MedPathMedPath Home
Clinical Trials/CTIS2022-500706-18-01
CTIS2022-500706-18-01
Recruiting
Phase 1

A phase I trial to assess safety and immunogenicity of an HLAII-targeted DNA vaccine against influenza H7N9

Oslo University Hospital Hf0 sites30 target enrollmentFebruary 28, 2023
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsInfluenza prophylaxisTherapeutic area: Diseases [C] - Virus Diseases [C02]

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Influenza prophylaxis
Sponsor
Oslo University Hospital Hf
Enrollment
30
Status
Recruiting
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
February 28, 2023
End Date
TBD
Last Updated
last year
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
Oslo University Hospital Hf

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting
Not Applicable
A Phase I trial to assess safety and immunogenicity of i.d. DNA priming and i.m. MVA boosting in healthy volunteers in MozambiqueHIV/AIDS
PACTR201106000304583Swedish Institute for Infectious Disease Control24
Completed
Phase 1
Study to evaluate safety and possible adverse reactions, especially serious, with a vaccine for measles and rubella in healthy subjects.Measles and Rubella
RBR-9hckj4Bio-Manguinhos/Fiocruz/MS
Unknown
Phase 2
HIVIS03
PACTR2009040001075080Swedish Institute for Infectious Disease Control (SMI)
Completed
Not Applicable
TaMoVac-01
PACTR2010050002122368Swedish Institute for Infectious Disease Control120
Completed
Not Applicable
Phase I clinical trial to assess safety and immunogenicity of an MVA-based influenza H5 vaccine in healthy adultsfluInfluenza10047438
NL-OMON38408Erasmus MC, Universitair Medisch Centrum Rotterdam27